What drug company is developing GW1516, a lipid to control cholesterol?
GW-501,516 (also known as GW1516 or GSK-516) is a drug developed by GlaxoSmithKline, which acts as a PPAR modulator. It activates AMP-activated protein kinase and stimulates glucose uptake in skeletal muscle tissue, and has been demonstrated to reverse metabolic abnormalities in obese men with pre-diabetic metabolic syndrome, most likely by stimulating fatty acid oxidation. It has been proposed as a potential treatment for obesity and related conditions, especially when used in conjunction with a synergistic compound AICAR, as the combination has been shown to significantly increase exercise endurance in animal studies. Concerns have been raised however that GW-501,516 or the GW-501,516 / AICAR combination could be used by athletes as a performance enhancing drug which is not currently controlled by regulations or detected by standard tests. One of the main researchers from the study on enhanced endurance has developed a urine test to detect the drug, and he has made it available to th
Related Questions
- Is it permissible for a drug representative from a pharmaceutical company to give an "update" on a product before the CME activity begins?
- Are there any recent innovations that the administration should consider when developing its drug control strategy?
- What does an investigator need to know about control of a drug?
